On April 18, 2007, AVANIR Pharmaceuticals announced positive top-line results from the Company's Phase III clinical trial evaluating the investigational drug AVP-923 (dextromethorphan/quinidine), formerly referred to by the proposed trade name Zenvia™, an NMDA antagonist and sigma-1 agonist, in diabetic peripheral neuropathic pain. The primary endpoint of the trial was based on the daily diary entries for the Pain Rating Scale as defined in the Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). In the trial, two doses of AVP-923, 45/30 mg DMQ dosed twice daily ("DMQ 45") and 30/30 mg DMQ dosed twice daily ("DMQ 30"), were compared to placebo based on daily patient diary entries for the Pain Rating Scale. Both AVP-923 treatment groups had lower pain ratings than placebo patients (p less than 0.0001 in both cases). Overall, the safety data from this study are consistent with data from previous studies.